These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 21958440

  • 1. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab.
    Carneiro AM, Costa R, Falcão MS, Barthelmes D, Mendonça LS, Fonseca SL, Gonçalves R, Gonçalves C, Falcão-Reis FM, Soares R.
    Acta Ophthalmol; 2012 Feb; 90(1):e25-30. PubMed ID: 21958440
    [Abstract] [Full Text] [Related]

  • 2. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, Bechrakis NE, Kieselbach GF.
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [Abstract] [Full Text] [Related]

  • 3. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF.
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of plasma vascular endothelial growth factor levels after intravitreal injection of ranibizumab and aflibercept for exudative age-related macular degeneration.
    Yoshida I, Shiba T, Taniguchi H, Takahashi M, Murano T, Hiruta N, Hori Y, Bujo H, Maeno T.
    Graefes Arch Clin Exp Ophthalmol; 2014 Sep; 252(9):1483-9. PubMed ID: 25030237
    [Abstract] [Full Text] [Related]

  • 5. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration.
    Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M.
    Am J Ophthalmol; 2014 Oct; 158(4):738-744.e1. PubMed ID: 24973606
    [Abstract] [Full Text] [Related]

  • 6. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE, Kanadani TM, Pereira FB, Nehemy MB.
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [Abstract] [Full Text] [Related]

  • 7. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
    Zehetner C, Bechrakis NE, Stattin M, Kirchmair R, Ulmer H, Kralinger MT, Kieselbach GF.
    Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
    [Abstract] [Full Text] [Related]

  • 8. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.
    Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Couvillion S, Nasir MA, Rabena MD, Le K, Maia M, Visich JE.
    Br J Ophthalmol; 2014 Dec; 98(12):1636-41. PubMed ID: 25001321
    [Abstract] [Full Text] [Related]

  • 9. Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab.
    Sizmaz S, Kucukerdonmez C, Kal A, Pinarci EY, Canan H, Yilmaz G.
    Eur J Ophthalmol; 2014 Dec; 24(6):904-10. PubMed ID: 24803153
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long-term alterations of systemic vascular endothelial growth factor levels in patients treated with ranibizumab for age-related macular degeneration.
    Enders P, Muether PS, Hermann M, Ristau T, Fauser S.
    Retina; 2015 Mar; 35(3):454-8. PubMed ID: 25170863
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.
    Kent JS, Iordanous Y, Mao A, Powell AM, Kent SS, Sheidow TG.
    Can J Ophthalmol; 2012 Apr; 47(2):159-64. PubMed ID: 22560422
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.